Abstract 548P
Background
Lung cancer is the malignant tumor with the highest incidence rate and mortality in the world. The main types of lung cancer are nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC). With targeted therapy and immunotherapy emerging, treating NSCLC has made a great progress. However, the molecular mechanisms underlying progression of NSCLC remain elusive.
Methods
Completing gain- and loss-of-function experiments to view whether B-Myb regulates the function of lung cancer cells by targeting IGFBP3 in lung cancer cell lines H1299 and A549, respectively. Mechanistically, Using a stable strain of B-Myb lung cancer to build the animal model and collecting mouse blood to lymphocyte subgroup analysis by flow cytometry. Analyzing metabolic products of lung cancer by metabolomics.
Results
B-Myb increased in lung cancer tissues and cells notably, its expression interrelated with clinical stage and poor prognosis of patients with NSCLC. B-Myb may affect the proliferation, invasion, and migration of NSCLC by regulating IGFBP3. Importantly, overexpressing of B-Myb in NSCLC affects the expression of immune checkpoint PD-1/PD-L1 and lung cancer cell metabolism.
Conclusions
Our findings reveal that B-Myb may interact with IGFBP3 to promote the occurrence and development of NSCLC and affect immune checkpoints PD-1/PD-L1 expressing. B-Myb may become a potential new target for the diagnosis and treatment of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chongqing Municipal Education Commission.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract